In this episode of the China biopharma English-language podcast, Xu Hu talks about recently China releasing two guidelines related to CAR-T therapies within a month and the strategic position that the country puts its cell therapy sector. The Pink Sheet stories related to this episode: CAR-T Guidelines Signal China’s Next Phase Of Cell Therapy Regulatory System Building CAR-Ts Win Big In New China Drug Coverage Lists